MTOR and neuroendocrine neoplasm: Advanced neuroendocrine tumors originating in the intestinal tract and pancreas are treated with biologics that activate somatostatin receptors (lanreotide and octreotide), small molecule drugs that target the mTOR (everolimus) and VEGF and other signaling pathways (sunitinib), chemotherapies (temozolomide, capecitabine, fluorouracil, platinums), and receptor-targeted radionuclides (Lu177-DOTATATE).